Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Disitamab Vedotin as Neoadjuvant Therapy for Eyelid Sebaceous Gland Carcinoma
NCT07740993Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, disitamab vedotin in sebaceous gland carcinoma (SGC), sponsored by West China Hospital of Sichuan University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sintilimabdisitamab vedotin
03
Conditions
sebaceous gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT07740993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07740993.